ARS Pharmaceuticals (SPRY) reported a Q2 net loss late Thursday of $0.63 per diluted share, widening from a loss of $0.46 a year earlier.
Four analysts polled by FactSet expected a loss of $0.48.
Revenue for the quarter ended June 30 was $33.7 million, up from $15.7 million a year earlier.
Four analysts expected $31.3 million.
The company said it had $143.8 million in cash, cash equivalents, and short-term investments as of June 30, and expects to reach cash flow breakeven by the end of 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.